Persistence of the immune response after MenACWY-CRM vaccination and response to a booster dose, in adolescents, children and infants

References

• Harrison LH, Trotter CL, Ramsay ME. Global epidemiology of meningococcal disease. Vaccine 2009; 27 Suppl 2:B51-863; PMID:19477562; http://dx.doi.org/10.1016/j.vaccine.2009.04.063
   PubMed Web of Science ®Google Scholar
• Christensen H, May M, Bowen L, Hickman M, Trotter CL. Meningococcal carriage by age: a systematic review and meta-analysis. Lancet Infect Dis 2010; 10:853-61; PMID:21075057; http://dx.doi.org/10.1016/S1473-3099(10)70251-6
   PubMed Web of Science ®Google Scholar
• Cohn AC, MacNeil JR, Clark TA, Ortega-Sanchez IR, Briere EZ, Meissner HC, Baker CJ, Messonnier NE, Centers for Disease Control and Prevention (CDC). Prevention and control of meningococcal disease: Recommendations of the Advisory Committee on Immunization Practices (ACIP). Recommendations Rep March 2013. 66(RR02);1-22 [accessed November 2015]. Available at: http://www.cdc.gov/mmwr/preview/mmwrhtml/rr6202a1.htm
   Google Scholar
• National Health Service, UK. The NHS vaccination schedule, April 2014. [accessed November 2015]. Available at: http://www.nhs.uk/Conditions/vaccinations/Pages/vaccination-schedule-age-checklist.aspx
   Google Scholar
• Departamento de Actualización Profesional. Boletín Official 33.085, 12 March 2015. [accessed November 2015] Available at http://www.colfarsfe.org.ar/newsfiles/marzo2015/Disposiciones12-03-15.pdf
   Google Scholar
• Ministry of Health Portal, Kingdom of Saudi Arabia. Basic vaccination schedule [accessed November 2015]. Available at: http://www.moh.gov.sa/en/HealthAwareness/EducationalContent/HealthTips/Pages/Tips-005.aspx
   Google Scholar
• Reisinger KS, Baxter R, Block SL, Shah J, Bedell L, Dull PM. Quadrivalent meningococcal vaccination of adults: phase III comparison of an investigational conjugate vaccine, MenACWY-CRM, with the licensed vaccine, Menactra. Clin Vaccine Immunol 2009; 16:1810-15; PMID:19812260; http://dx.doi.org/10.1128/CVI.00207-09
   PubMed Web of Science ®Google Scholar
• Halperin SA, Gupta A, Jeanfreau R, Klein NP, Reisinger K, Walter E, Bedell L, Gill C, Dull PM. Comparison of the safety and immunogenicity of an investigational and a licensed quadrivalent meningococcal conjugate vaccine in children 2-10 years of age. Vaccine 2010; 28:7865-72; PMID:20943209; http://dx.doi.org/10.1016/j.vaccine.2010.09.092
   PubMed Web of Science ®Google Scholar
• Klein NP, Reisinger KS, Johnston W, Odrljin T, Gill CJ, Bedell L, Dull P. Safety and immunogenicity of a novel quadrivalent meningococcal CRM-conjugate vaccine given concomitantly with routine vaccinations in infants. Pediatr Infect Dis J 2012; 31:64-71; PMID:22094635; http://dx.doi.org/10.1097/INF.0b013e31823dce5c
   PubMed Web of Science ®Google Scholar
• Tregnaghi M, Lopez P, Stamboulian D, Graña G, Odrljin T, Bedell L, Dull PM. Immunogenicity and safety of a quadrivalent meningococcal polysaccharide CRM conjugate vaccine in infants and toddlers. Int J Infect Dis 2014; 26:22-e30; PMID:24980467; http://dx.doi.org/10.1016/j.ijid.2014.03.1390
   PubMed Web of Science ®Google Scholar
• Johnston W, Essink B, Kirstein J, Forleo-Neto E, Percell S, Han L, Keshavan P, Smolenov I. Comparative Assessment of a 2-dose and a 1–dose vaccination series of a Quadrivalent Meningococcal conjugate vaccine (MenACWY-CRM) in children 2-10 years of age. Pediatr Infect Dis J 2016;35:e19-27; PMID:26398741; http://dx.doi.org/10.1097/INF.0000000000000931
   Web of Science ®Google Scholar
• Gill CJ, Baxter R, Anemona A, Ciavarro G, Dull P. Persistence of immune responses after a single dose of Novartis meningococcal serogroup A, C, W-135 and Y CRM-197 conjugate vaccine (Menveo®) or Menactra® among healthy adolescents. Hum Vaccin 2010; 6:881-7; PMID:21339701; http://dx.doi.org/10.4161/hv.6.11.12849
   PubMed Web of Science ®Google Scholar
• Baxter R, Reisinger K, Block SL, Izu A, Odrljin Dull P. Antibody persistence and booster response of a quadrivalent meningococcal conjugate vaccine in adolescents. J Pediatr 2014; 164:1409-15; PMID:24657122; http://dx.doi.org/10.1016/j.jpeds.2014.02.025
   PubMed Web of Science ®Google Scholar
• Baxter R, Reisinger K, Block S, Percell S, Odrljin T, Dull PM, Smolenov I. Antibody persistence after primary and booster doses of a quadrivalent meningococcal conjugate vaccine in adolescents. Pediatr Infect Dis J 2014; 33:1169-76; PMID:24911896; http://dx.doi.org/10.1097/INF.0000000000000438
   PubMed Web of Science ®Google Scholar
• Block SL, Christensen S, Verma B, Xie F, Keshavan P, Dull PM, Smolenov I. Antibody persistence 5 years after vaccination at 2 to 10 years of age with Quadrivalent MenACWY-CRM conjugate vaccine, and responses to a booster vaccination. Vaccine 2015:33:2175-82; PMID:25744224; http://dx.doi.org/10.1016/j.vaccine.2015.02.049
   PubMed Web of Science ®Google Scholar
• Klein NP, Block SL, Johnston W, Percell S, Han L, Dull PM, et al. Persistence of meningococcal bactericidal antibodies and booster response at 60-months of age in children who received infant or toddler doses of MenACWY-CRM conjugate vaccine. Presented at the Infectious Diseases Society of America 2014, Philadelphia PA, USA. [Accessed February 9, 2016.] Available at: https://idsa.confex.com/idsa/2014/webprogram/Paper45999.html.
   Google Scholar
• Klein NP, Block SL, Johnston W, Percell S, Keshavan P, Dull PM et al. Persistence of meningococcal antibodies after infant and toddler MenACWY-CRM conjugate vaccine assessed with serum bactericidal assays using human and rabbit complement. Presented at Meningitis Res Found 2015, London UK. [Accessed February 9, 2016] Available at: http://www.meningitis.org/assets/x/57410
   Google Scholar
• Borrow R, Andrews N, Goldblatt D, Miller E. Serological basis for the use of meningococcal serogroup C conjugate vaccines in the United Kingdom: Reevaluation of the correlates of protection. Infect Immun 2001; 59:1568-73; http://dx.doi.org/10.1128/IAI.69.3.1568-1573.2001
   Web of Science ®Google Scholar
• Findlow H, Plikaytis BD, Aase A, Bash MC, Chadha H, Elie C, Laher G, Martinez J, Herstad T, Newton E, et al. Investigation of different group A immunoassays following one dose of meningococcal group A conjugate vaccine or A/C polysaccharide vaccine in adults. Clin Vaccine Immunol 2009; 16:969-77; PMID:19474264; http://dx.doi.org/10.1128/CVI.00068-09
   PubMed Web of Science ®Google Scholar
• McIntosh ED, Bröker M, Wassil J, Welsch JA, Borrow R. Serum bactericidal antibody assays - The role of complement in infection and immunity. Vaccine 2015; 33:4414-21; PMID:26187262; http://dx.doi.org/10.1016/j.vaccine.2015.07.019
   PubMed Web of Science ®Google Scholar
• Andrews N, Borrow R, Miller E. Validation of serological correlate of protection for meningococcal C conjugate vaccine by using efficacy estimates from post licensure surveillance in England. Clin Diagn Lab Immunol 2003; 10:780-6; PMID:12965904
   PubMedGoogle Scholar
• Goldschneider I, Gotschlich EC, Artenstein MS. Human immunity to the Meningococcus I. The role of humoral antibodies. J Exp Med 1969; 129:1307-26; PMID:4977280; http://dx.doi.org/10.1084/jem.129.6.1307
   PubMed Web of Science ®Google Scholar
• Goldschneider I, Gotschlich EC, Artenstein MS. Human immunity to the Meningococcus II. Development of natural immunity. J Exp Med 1969; 129:1327-48; PMID:4977281; http://dx.doi.org/10.1084/jem.129.6.1327
   PubMed Web of Science ®Google Scholar
• Auckland C, Gray S, Borrow R, Andrews N, Goldblatt D, Ramsay M, Miller E. Clinical and immunologic risk factors for meningococcal C conjugate vaccine failure in the United Kingdom. J Infect Dis 2006; 194:1745-52; PMID:17109348; http://dx.doi.org/10.1086/509619
   PubMed Web of Science ®Google Scholar
• Snape MD, Kelly DF, Salt P, Green S, Snowden C, Diggle L, Borkowski A, Yu LM, Moxon ER, Pollard AJ. Serogroup C meningococcal glycoconjugate vaccine in adolescents: persistence of bactericidal antibodies and kinetics of the immune response to a booster vaccine more than 3 years after immunization. Clin Infect Dis 2006; 43:1387-94; PMID:17083009; http://dx.doi.org/10.1086/508776
   PubMed Web of Science ®Google Scholar
• Baxter R, Baine Y, Kolhe D, Baccarini CI, Miller JM, Van der Wielen M. Five-year antibody persistence and booster response to a single dose of meningococcal A, C, W, and Y tetanus toxoid conjugate vaccine in adolescents and young adults: an open, randomized trial. Pediatr Infect Dis J 2015; 34:1236-43; PMID:26237742; http://dx.doi.org/10.1097/INF.0000000000000866
   PubMed Web of Science ®Google Scholar
• De Wals P. Immunization strategies for the control of serogroup C meningococcal disease in developed countries. Expert Rev Vaccines 2006; 5:269-75; PMID:16608426; http://dx.doi.org/10.1586/14760584.5.2.269
   PubMed Web of Science ®Google Scholar
• Borrow R, Abad R, Trotter C, van der Klis FR, Vazquez JA. Effectiveness of meningococcal serogroup C vaccine programmes. Vaccine 2013; 31:4477-86; PMID:23933336; http://dx.doi.org/10.1016/j.vaccine.2013.07.083
   PubMed Web of Science ®Google Scholar
• Snape MD, Perrett KP, Ford KJ, John TM, Pace D, Yu LM, Langley JM, McNeil S, Dull PM, Ceddia F, et al. Immunogenicity of a tetravalent meningococcal glycoconjugate vaccine in infants: a randomized controlled trial. JAMA 2008; 299:173-84; PMID:18182599; http://dx.doi.org/10.1001/jama.2007.29-c
   PubMed Web of Science ®Google Scholar
• Klein NP, Baine Y, Bianco V, Lestrate PR, Naz A, Blatter M, Friedland LR, Miller JM. One or two doses of quadrivalent meningococcal serogroups A, C, W-135 and Y tetanus toxoid conjugate vaccine is immunogenic in 9- to 12-month-old children. Pediatr Infect Dis J 2013; 32:760-7; PMID:23348814; http://dx.doi.org/10.1097/INF.0b013e31828693c5
   PubMed Web of Science ®Google Scholar
• Vesikari T, Forsten A, Boutriau D, Bianco V, Van der Wielen M, Miller JM. Randomized trial to assess the immunogenicity, safety and antibody persistence up to three years after a single dose of a tetravalent meningococcal serogroups A, C, W-135 and Y tetanus toxoid conjugate vaccine in toddlers. Hum Vaccines Immunother 2012; 8:1892-903; http://dx.doi.org/10.4161/hv.22166
   PubMed Web of Science ®Google Scholar
• Plested JS, Granoff DM. Vaccine-induced opsonophagocytic immunity to Neisseria meningitidis group B. Clin Vaccine Immunol 2008; 15:799-804; PMID:18353918; http://dx.doi.org/10.1128/CVI.00036-08
   PubMed Web of Science ®Google Scholar
• Welsch JA, Granoff DM. Naturally acquired passive protective activity against Neisseria meningitidis Group C in the absence of serum bactericidal activity. Infect Immun 2004; 72:5903-09; PMID: 15385492; http://dx.doi.org/10.1128/IAI.72.10.5903-5909.2004
   PubMed Web of Science ®Google Scholar
• Pajon R, Buckwalter CM, Johswich KO, Gray-Owen SD, Granoff DM. A native outer membrane vesicle vaccine confers protection against meningococcal colonization in human CEACAM1 transgenic mice. Vaccine 2015; 33:1317-23; PMID:25662856; http://dx.doi.org/10.1016/j.vaccine.2015.01.057
   PubMed Web of Science ®Google Scholar
• Gorringe AR, Reddin KM, Funnell SG, Johansson L, Rytkonen A, Jonsson AB. Experimental disease models for the assessment of meningococcal vaccines. Vaccine 2005; 23:17-18
   Google Scholar
• Borrow R, Balmer P, Miller E. Meningococcal surrogates of protection-serum bactericidal antibody activity. Vaccine 2005; 23:2222-27; PMID:15755600; http://dx.doi.org/10.1016/j.vaccine.2005.01.051
   PubMed Web of Science ®Google Scholar
• Maslanka SE, Gheesling LL, Libutti DE, Donaldson KB, Harakeh HS, Dykes JK, Arhin FF, Devi SJ, Frasch CE, Huang JC, et al. Standardization and a multilaboratory comparison of Neisseria meningitidis serogroup A and C serum bactericidal assays. The ultilaboratory Study Group. Clin Diagn Lab Immunol 1997; 4:156-167; PMID:9067649
   PubMedGoogle Scholar
• Balmer P, Borrow R. Issues surrounding standardization of meningococcal serogroup W135 serology. Vaccine 2007; 25 (Suppl 1):A63-A68; PMID:17544550; http://dx.doi.org/10.1016/j.vaccine.2007.04.043
   PubMedGoogle Scholar
• Borja-Tabora C, Montalban C, Memish ZA, Van der Wielen M, Bianco V, Boutriau D, Miller J. Immune response, antibody persistence, and safety of a single dose of the quadrivalent meningococcal serogroups A, C, W-135, and Y tetanus toxoid conjugate vaccine in adolescents and adults: results of an open, randomised, controlled study. BMC Infect Dis 2013; 13:116; PMID:23510357; http://dx.doi.org/10.1186/1471-2334-13-116
   PubMed Web of Science ®Google Scholar
• Østergaard L, Van der Wielen M, Bianco V, Miller JM. Persistence of antibodies for 42 months following vaccination of adolescents with a meningococcal serogroups A, C, W-135, and Y tetanus toxoid conjugate vaccine (MenACWY-TT). Int J Infect Dis 2013; 17: e173-6; http://dx.doi.org/10.1016/j.ijid.2012.10.001
   PubMed Web of Science ®Google Scholar
• Pichichero M, Casey J, Blatter M, Rothstein E, Ryall R, Bybel M, Gilmet G, Papa T. Comparative trial of the safety and immunogenicity of quadrivalent (A, C, Y, W-135) meningococcal polysaccharide-diphtheria conjugate vaccine versus quadrivalent polysaccharide vaccine in two- to ten-year-old children. Pediatr Infect Dis J 2005; 24:57-62; PMID:15665711; http://dx.doi.org/10.1097/01.inf.0000148928.10057.86
   PubMed Web of Science ®Google Scholar
• Pichichero M, Papa T, Blatter M, Mitchell D, Kratz R, Sneed J, Bassily E, Casey J, Gilmet G. Immune memory in children previously vaccinated with an experimental quadrivalent meningococcal polysaccharide diphtheria toxoid conjugate vaccine. Pediatr Infect Dis J 2006; 25:995-1000; PMID:17072120; http://dx.doi.org/10.1097/01.inf.0000243215.46312.4a
   PubMed Web of Science ®Google Scholar
• Vesikari T, Forsten A, Bianco V, Van Der Wielen M, Miller JM. Antibody persistence up to five years after vaccination of toddlers and children between 12 months and 10 years of age with a quadrivalent meningococcal ACWY-tetanus toxoid conjugate vaccine. Hum Vaccin Immunother. 2015 Dec;34:e298-307; PMID:26780033; http://dx.doi.org/10.1097/INF.0000000000000897
   Web of Science ®Google Scholar
• Yaro S, Tall H, Kpoda H, Ouangraoua S, Trotter C, Njanpop Lafourcade B-M, et al. Meningococcal seroepidemiology in Burkina Faso, one year after the MenAfriVac® campaign. Presented at the Meningitis Research Foundation Conference 2013, London UK. [Accessed February 9, 2016] Available at: http://www.meningitis.org/assets/x/55419
   Google Scholar
• Kristiansen PA, Ba AK, Ouédraogo AS, Sanou I, Ouédraogo R, Sangaré L, Diomandé F, Kandolo D, Saga IM, Misegades L, et al. Persistent low carriage of serogroup A Neisseria meningitidis two years after mass vaccination with the meningococcal conjugate vaccine, MenAfriVac. BMC Infect Dis 2014; 14:663-74; PMID:25472422; http://dx.doi.org/10.1186/s12879-014-0663-4
   PubMed Web of Science ®Google Scholar
• Daugla DM, Gami JP, Gamougam K, Naibei N, Mbainadji L, Narbé M, Toralta J, Kodbesse B, Ngadoua C, Coldiron ME, et al. Effect of a serogroup A meningococcal conjugate vaccine (PsA-TT) on serogroup A meningococcal meningitis and carriage in Chad: a community study [corrected]. Lancet 2014; 383:40-47; PMID:24035220; http://dx.doi.org/10.1016/S0140-6736(13)61612-8
   PubMed Web of Science ®Google Scholar
• Price G, Plikaytis B, Hollander A, Mocca B, Carlone G, Findlow H, et al. Comparison of different serogroup A immunoassays following a single dose of either MenAfriVac or quadrivalent polysaccharide vaccine in healthy Africans 2- to 29- years of age. Presented at International Pathogenic Neisseria Conferences 2014, Asheville NC, USA. [Accessed February 9, 2016] Available at: http://neisseria.org/ipnc/2014/IPNC_2014_abstracts.pdf
   Google Scholar
• Plested JS, Welsch JA, Granoff DM. Ex-vivo model of meningococcal bacteremia using human blood for measuring vaccine-induced serum passive protective activity. Clin Vaccine Immunol 2009; 16:785-91; PMID:19339487; http://dx.doi.org/10.1128/CVI.00007-09
   PubMed Web of Science ®Google Scholar
• Norheim G, Aase A, Caugant DA, Hølby EA, Fritzsønn E, Tangen T, Kristiansen P, Heggelund U, Rosenqvist E. Development and characterization of outer membrane vesicle vaccines against serogroup A Neisseria meningitidis. Vaccine 2005. 23:3762-74; PMID:15893613; http://dx.doi.org/10.1016/j.vaccine.2005.02.021
   PubMed Web of Science ®Google Scholar
• Plested JS, Ferry BL, Coull PA, Makepeace K, Lehmann AK, MacKinnon FG, Griffiths HG, Herbert MA, Richards JC, Moxon ER. Functional opsonic activity of human serum antibodies to inner core lipopolysaccharide (galE) of serogroup B meningococci measured by flow cytometry. Infect Immun 2001. 69:3203-13; PMID:11292742; http://dx.doi.org/10.1128/IAI.69.5.3203-3213.2001
   PubMed Web of Science ®Google Scholar
• Jacobson RM, Jackson LA, Reisinger K, Izu A, Odrljin T, Dull PM. Antibody persistence and response to a booster dose of a quadrivalent conjugate vaccine for meningococcal disease in adolescents. Pediatr Infect Dis J 2013; 32: e170-7; PMID:23114372; http://dx.doi.org/10.1097/INF.0b013e318279ac38
   PubMed Web of Science ®Google Scholar
• Borrow R, Goldblatt D, Finn A, Southern J, Ashton L, Andrews N, Lal G, Riley C, Rahim R, Cartwright K, et al. Immunogenicity of, and immunologic memory to, a reduced primary schedule of meningococcal C-tetanus toxoid conjugate vaccine in infants in the United Kingdom. Infect Immun 2003; 71:5549-55; PMID:14500473; http://dx.doi.org/10.1128/IAI.71.10.5549-5555.2003
   PubMed Web of Science ®Google Scholar